Brief: Galectin Therapeutics Ends Enrollment Of Navigate, Its Seamless, Adaptive Phase 2b/3 Study Of Belapectin
05/01/2023 13:52
Jan 5 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS ANNOUNCES THE END OF ENROLLMENT OF
NAVIGATE, ITS SEAMLESS, ADAPTIVE PHASE 2B/3 STUDY OF BELAPECTIN
IN PATIENTS WITH LIVER CIRRHOSIS CAUSED BY NON-ALCOHOLIC
STEATOHEPATITIS
* GALECTIN THERAPEUTICS INC - RESULTS OF THE INTERIM
ANALYSIS OF
PHASE 2B PORTION OF NAVIGATE ARE EXPECTED IN THE FOURTH QUARTER
OF 2024
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study